What is Evolus?
Evolus operates as a performance beauty company dedicated to the development and commercialization of advanced aesthetic products. Its market position is anchored by its flagship neurotoxin, Jeuveau, which serves as a primary solution for the temporary improvement of glabellar lines. Beyond its neurotoxin offerings, the company has strategically diversified its portfolio with the introduction of Evolysse, a suite of hyaluronic acid dermal fillers. By combining pharmaceutical-grade innovation with a digital-first customer engagement platform, Evolus effectively bridges the gap between clinical efficacy and consumer-facing beauty trends, catering specifically to the growing demand for non-surgical facial rejuvenation.
How much funding has Evolus raised?
Evolus has raised a total of $40M across 1 funding round:
Other Financing Round
$40M
Other Financing Round (2020): $40M with participation from Daewoong Pharmaceutical Co. Ltd
Key Investors in Evolus
Daewoong Pharmaceutical Co. Ltd
A leading South Korean pharmaceutical company specializing in the development of innovative therapeutics and medical aesthetic products.
What's next for Evolus?
With the backing of major strategic partners, Evolus is well-positioned to scale its operations and deepen its penetration into the global aesthetics market. The current funding trajectory suggests a focus on expanding the reach of the Evolysse line while maintaining the momentum of the Jeuveau brand. Future strategic initiatives will likely involve enhancing the digital infrastructure that supports its customer-centric model, allowing for more efficient distribution and provider engagement. As the company matures, the emphasis will shift toward sustaining long-term growth through clinical excellence and the continued optimization of its supply chain, ensuring that its aesthetic solutions remain at the forefront of the cash-pay market.
See full Evolus company page
